Loading…
Approval granted to West Cancer Center to commence the study.
IceCure Medical Ltd. announced that West Cancer Center has received Institutional Review Board (IRB) approval to commence the ChoICE Study, a clinical trial evaluating the use of IceCure's cryoablation technology for the treatment of breast cancer.
The ChoICE Study aims to assess the safety and efficacy of cryoablation as an alternative to traditional surgical methods for early-stage breast cancer. The trial will enroll patients at West Cancer Center, with data expected to contribute to the growing body of evidence supporting cryoablation as a viable treatment option.
As of the latest available data, IceCure Medical Ltd. has a free float of 1,735,005 shares and 3,426,375 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.